Fulcrum Therapeutics Company Profile

15:29 EDT 19th September 2019 | BioPortfolio

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit

News Articles [926 Associated News Articles listed on BioPortfolio]

Fulcrum Therapeutics buys rights to losmapimod from GSK

Fulcrum Therapeutics has entered an exclusive global licence agreement with GlaxoSmithKline (GSK) for rights to investigational drug losmapimod. The agreement...Read More... The post Fulcrum Therapeut...

Fulcrum Therapeutics Licenses Failed GSK Drug for Possible Muscular Dystrophy Indication

Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.

Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD

CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...

GSK grants Fulcrum rights to losmapimod

Fulcrum Therapeutics has acquired an exclusive, worldwide license to develop and market GlaxoSmithKline's losmapimod, a p38 k -More- 

Fulcrum nets $67mm through IPO

Fulcrum Therapeutics Inc. (focused on genetically defined rare diseases) netted $67mm in its initial public offering of 4.5mm shares at $16, the low end of its anticipated $16-18 range.

#news #biotech Fulcrum bags failed GSK drug, plots muscle wasting pivot

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Fulcrum bags failed GSK drug, plots muscle wasting pivot .GlaxoSmithKline has...

Fulcrum Acquires Global Rights to Losmapimod, a Potential Therapy for Facioscapulohumeral Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Fulcrum Therapeutics, a biotechnology company focused on discovering and developing therapies to rebalance gene expression, today announced an exclusive wo...

Fulcrum acquires global rights of investigational drug losmapimod from GSK

Under an exclusive worldwide license agreement, Fulcrum will develop and commercialize losmapimod, a potential disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is p...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]


Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]


Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [445 Associated PubMed Articles listed on BioPortfolio]

Selection of Lowest Instrumented Vertebra Using Fulcrum Bending Radiographs Achieved Shorter Fusion Safely Compared with the Last "Substantially" Touching Vertebra in Lenke Type 1A and 2A Curves.

Retrospective study with prospective radiographic data collection.

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Clinical Trials [188 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1376 Associated Companies listed on BioPortfolio]

Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum...

Fulcrum Pharma Developments Inc

Fulcrum Pharma Developments works with biotech and pharmaceutical companies to mitigate the risks associated with drug development. Fulcrum’s development specialists work as an extension of your dev...

Fulcrum SP Ltd.

Established in January 2001 and headquartered in Rehovot, Israel, Fulcrum SP Ltd. is a biotechnological company focused on the research and application of high-performance stable proteins. The company...

Fulcrum Pharma Developments Limited

Fulcrum Pharma is an independent public company that is the first to offer global virtual drug development and strategic outsourcing services to the pharmaceutical and biotechnology industries. Fulcru...

Fulcrum Methods

More Information about "Fulcrum Therapeutics" on BioPortfolio

We have published hundreds of Fulcrum Therapeutics news stories on BioPortfolio along with dozens of Fulcrum Therapeutics Clinical Trials and PubMed Articles about Fulcrum Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fulcrum Therapeutics Companies in our database. You can also find out about relevant Fulcrum Therapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record